In this guide
What is Borage Oil?
Borage oil is a concentrated GLA source. Older rheumatoid-arthritis trials do not establish self-treatment, and pyrrolizidine-alkaloid control is a product-quality requirement. No U.S. DRI or established daily requirement exists for borage oil or supplemental GLA.
Typical Borage Oil Protocols
| Source and population | Form and amount each time | Frequency | Total exposure | Duration or boundary |
|---|---|---|---|---|
| Leventhal 1993 · 37 adults with active rheumatoid arthritis | Borage seed oil supplying 1.4 g GLA/day | Daily total; administration count not recovered | 1.4 g GLA/day | 24 weeks |
| Reed 2014 · rheumatoid arthritis | Borage oil supplying 1.8 g GLA/day | Administration count not recovered | 1.8 g GLA/day | 18 months; fish, borage and combination groups |
| Quality audit | Oil, GLA and pyrrolizidine-alkaloid testing | Each lot | No inferred safe PA exposure | Before use and at every product change |
These rows reproduce sources. Do not average them into one universal regimen.
From source to outcome
Not total oil mass.
37 people · 24 weeks.
Avoid unverified product.
Which forms and label details matter?
Record borage-oil mass and GLA separately. Require a finished product tested for pyrrolizidine alkaloids; the plant, leaf extract and seed oil are not interchangeable.
How should it be stored?
Follow the label, close the container and protect it from heat, light and moisture.
Read the label before the claim
Match the studied preparation.
Keep the daily total visible.
A biomarker is not a clinical event.
What is it commonly used for?
Borage oil is promoted for rheumatoid arthritis, eczema and skin moisture. Evidence is older, small and formulation-specific; it does not replace disease-modifying treatment.
What does human research show?
Leventhal randomized 37 people with active rheumatoid arthritis to borage oil providing 1.4 g GLA/day or cottonseed oil for 24 weeks and reported improvements in tender and swollen joints. The very small, older trial explicitly cautioned that GLA was not approved as treatment. [1] Reed’s 18-month randomized trial compared borage oil, fish oil and their combination; all groups improved, but there was no significant between-group difference and registry comparisons complicated attribution. [2] Cochrane evidence does not support oral borage or evening primrose oil as an effective eczema treatment. [3] Positive mechanisms or within-group change do not justify stopping disease-modifying antirheumatic therapy.
How might it act?
Fatty acids enter membranes, serve as energy substrates or act as precursors to mediators according to their structure. This mechanism does not turn a blood-level change into prevention of a clinical event.
How does it compare with related products?
| Product | What the label needs to state | Practical distinction |
|---|---|---|
| Fish oil | EPA, DHA and total oil | Marine EPA+DHA mixture; findings from an EPA-only prescription drug do not automatically transfer. |
| Krill oil | EPA, DHA, phospholipids and shellfish source | Different source with a shellfish allergen; total oil mass does not reveal EPA+DHA mass. |
| Algal oil | DHA, any EPA and total oil | Non-fish source; formulations can be mainly DHA. |
| Cod liver oil | EPA, DHA, vitamin A and vitamin D | Adds fat-soluble vitamins that must be counted with other products. |
What are the risks and interactions?
Potential pyrrolizidine-alkaloid contamination is a liver concern. Avoid unverified products and review liver disease, pregnancy, breastfeeding, anticoagulants, antiplatelets, surgery and seizure risk. Seek rheumatology care for inflammatory arthritis. [4]
Which medicines require review?
Have the product reviewed with medicines, before surgery, and during pregnancy or breastfeeding. No universal separation interval is established.
Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [5], [6]
What should be monitored?
Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.
What happens when it is stopped?
No ingredient-specific withdrawal syndrome is established. Record the stop date, symptoms and chosen outcome; seek care for a persistent serious symptom.
Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.
What do public communities report?
Public reports can suggest questions to track, but they do not verify the product, dose or causality. This update did not newly quantify a community sample.
Common questions about Borage Oil
Does borage oil treat rheumatoid arthritis?
Small older trials are insufficient for self-treatment and do not replace DMARDs.
Is borage oil proven for eczema?
No. The pooled oral-oil evidence did not show meaningful benefit.
What are pyrrolizidine alkaloids?
Plant contaminants that can injure the liver; finished-product testing matters.
Is 1.4 g/day the oil dose?
No. It was the GLA daily total in one trial; oil mass was higher.
Can I use borage leaves instead?
No. Leaf products and seed oil differ, including toxicology.
What should I track?
Product, lot, GLA, oil mass, PA-testing evidence, medications, symptoms and review date.
Glossary
Terms for reading the evidence.
- ALA
- Essential 18-carbon omega-3; adult AIs refer to this form.
- EPA
- Long-chain omega-3; distinct from total oil weight.
- DHA
- Long-chain omega-3; often present in a different amount from EPA.
- Amount per administration
- Amount consumed at one time, distinct from daily total.
- Biomarqueur
- Biological measure that is not necessarily a clinical benefit.
- UL
- Tolerable Upper Intake Level established for a nutrient and defined scope.
How this guide was researched
Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.
How this guide was made
Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.
Explore the sources
Sources preserve form, amount, frequency, population, duration and outcome.
Showing 6 sources
- 01
Treatment of rheumatoid arthritis with gammalinolenic acid. ↗
Small randomized trial with linked editorial comment
Current page or report reviewed; scope and limits retained.
Detail: 37 participants; 1.4 g GLA/day in borage oil for 24 weeks. NCBI links a 1994 CommentIn letter (PMID:8135457; DOI:10.7326/0003-4819-120-8-199404150-00014), not a correction or retraction.
- 02
Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial. ↗
Long randomized comparative trial
Current page or report reviewed; scope and limits retained.
Detail: 18 months; no significant difference among fish, borage and combination groups.
- 03
Oral evening primrose oil and borage oil for eczema. ↗
Cochrane systematic review
Current page or report reviewed; scope and limits retained.
Detail: Oral oils did not meaningfully improve eczema.
- 04
Borage ↗
Institutional safety overview
Current page or report reviewed; scope and limits retained.
Detail: Pyrrolizidine-alkaloid, liver, pregnancy and interaction cautions.
- 05
Questions and Answers on Dietary Supplements ↗
U.S. regulatory overview
Current page or report reviewed; scope and limits retained.
Detail: Supplements generally lack efficacy preapproval.
- 06
Product Licensing ↗
Canadian licensing overview
Current page or report reviewed; scope and limits retained.
Detail: Finished natural health products require licensing and authorized labels.
No matching sources
Try a different term or show the full list.